Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA Holdings reported a strong fourth quarter for 2020, with revenue of $3,298 million, representing a 13.9% increase year-over-year. Technology & Analytics Solutions (TAS) grew 17.4%, while Research & Development Solutions (R&DS) increased 14.5%. However, Contract Sales & Medical Solutions (CSMS) revenue declined by 10%. The R&DS contracted backlog rose 18.5% to $22.6 billion. The company achieved an adjusted EBITDA of $735 million and raised its 2021 financial guidance, projecting revenues between $12,550 million and $12,900 million.
Summary not available.
Summary not available.
IQVIA Holdings Inc. (NYSE:IQV) will announce its fourth-quarter and full-year 2020 financial results on February 10, 2021, before the market opens. A conference call and webcast will be hosted by the management team at 9:00 a.m. ET on the same day. Interested parties must register in advance for the call. The earnings release and financial information will be available on the IQVIA Investor Relations website. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services within the life sciences industry, employing around 70,000 people across more than 100 countries.
IQVIA has partnered with Laboratoires Théa, a top independent eye care group in Europe, to implement its Orchestrated Customer Engagement (OCE) platform and the OneKey HCP/HCO reference database in over 22 markets. This collaboration aims to enhance Théa’s digital strategy and customer engagement, especially in the wake of changes prompted by the COVID-19 pandemic. The OCE platform integrates various functions to improve service delivery and relationships with healthcare professionals. IQVIA serves more than 125 life sciences companies with its innovative solutions.
Q2 Solutions, a clinical trial laboratory services organization formed from an IQVIA and Quest Diagnostics joint venture, has partnered with Adaptive Biotechnologies to provide advanced immune-driven research services. The collaboration introduces immunoSEQ® Assay and immunoSEQ® T-MAP™ COVID, enhancing testing capabilities for pharma clients, particularly in understanding immune responses related to COVID-19 and drug development. This partnership is poised to improve the drug development lifecycle through detailed immune response analytics.
Summary not available.
IQVIA (NYSE:IQV) has announced a collaboration with Servier to enhance its R&D clinical development processes through the SCORE program. This initiative aims to transform Servier's clinical trial applications and improve patient outcomes by utilizing optimized processes, data-driven insights, and innovative technology. Over the next two years, IQVIA will implement a robust program that leverages its expertise in R&D consulting, digital transformation, and technology solutions. The partnership is poised to address unmet medical needs and support Servier's ambitious growth plans.
IQVIA (NYSE: IQV) announced its support for the Real World Evidence Leadership Forum, uniting senior RWE executives from 18 pharmaceutical companies. This non-competitive group aims to address RWE challenges and enhance patient outcomes globally. Underlining the significance of real-world data, Dan Simpson of IQVIA stated that establishing trust in data usage is crucial. The forum's immediate focus includes fostering collaborative relationships between pharma and healthcare, promoting publications on trusted partnerships, and meeting biannually to tackle industry issues.
IQVIA announced that Zentiva is implementing its Orchestrated Customer Engagement (OCE) platform in 12 major markets. This partnership aims to enhance Zentiva's commercial operations and customer interactions. OCE will facilitate optimization of field processes and multi-channel marketing through AI/ML capabilities, benefiting sales and marketing teams. Paul Geymayer from Zentiva emphasized the importance of digitally enabling their teams to foster growth and efficiency.